cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Intercept Pharmaceuticals Inc
15 own
15 watching
Current Price
$0
$-0.44
(-2.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
899.17M
52-Week High
52-Week High
21.86
52-Week Low
52-Week Low
10.81
Average Volume
Average Volume
0.15M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization899.17M
icon52-Week High21.86
icon52-Week Low10.81
iconAverage Volume0.15M
iconDividend Yield--
iconP/E Ratio--
What does the Intercept Pharmaceuticals Inc do?
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More
How much money does Intercept Pharmaceuticals Inc make?
News & Events about Intercept Pharmaceuticals Inc.
Globe Newswire
20days ago
NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study demonstrating OCAs improvement in liver fibrosis without worsening of NASHPDUFA target action date set for June 22, 2023 MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE ...
Globe Newswire
1month ago
MORRISTOWN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief ...
Globe Newswire
1month ago
MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA...
Globe Newswire
1month ago
NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study NDA includes detailed safety analysis of 2,477 patients with nearly 1,000 patients on study drug for 4 years MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- ...
Globe Newswire
2 months ago
MORRISTOWN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Intercept Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Intercept Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Intercept Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Intercept Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Intercept Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Intercept Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Intercept Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Intercept Pharmaceuticals Inc?
plus_minus_icon
What percentage is Intercept Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Intercept Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.44
(-2.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Innoviva, Inc.
Innoviva, Inc.
$12.35
$-0.29 (-2.33 %)
Seres Therapeutics Inc
Seres Therapeutics Inc
$5.50
$0.06 (1.10 %)
Coherus BioSciences Inc
Coherus BioSciences Inc
$8.17
$-0.25 (-2.97 %)
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$27.11
$-1.01 (-3.59 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Innoviva, Inc.
Innoviva, Inc.
$12.35
$-0.29 (-2.33 %)
Seres Therapeutics Inc
Seres Therapeutics Inc
$5.50
$0.06 (1.10 %)
Coherus BioSciences Inc
Coherus BioSciences Inc
$8.17
$-0.25 (-2.97 %)
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$27.11
$-1.01 (-3.59 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00